Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Chronic Rhinosinusitis With Nasal Polyps
NCT06338995Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of lebrikizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Eli Lilly and Company. Started Apr 2024; status: recruiting.
02
Drugs
lebrikizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06338995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06338995.